## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($327.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Accurate Wealth Management LLC Takes Position in Cencora, Inc. $COR**
- Source: MarketBeat | 20260101T080837 | Somewhat-Bullish | Relevance: 100%
- Accurate Wealth Management LLC has acquired 8,786 shares of Cencora (NYSE:COR) valued at $2.79 million during Q3. Despite recent insider selling, institutional investors hold 97.52% of the stock. Cencora exceeded Q3 EPS estimates, provided strong FY2026 guidance, and increased its quarterly dividend, maintaining a "Moderate Buy" analyst consensus.

**2. Cencora Stock: Quiet Rally, Firm Fundamentals and a Market Looking for the Next Catalyst**
- Source: AD HOC NEWS | 20251231T120817 | Bullish | Relevance: 100%
- Cencora (CINC) has been experiencing a quiet but steady rally, outperforming broader healthcare distributors due to firm fundamentals and institutional demand. The stock, trading near its 52-week high, has delivered significant double-digit returns over the past year, driven by strong execution in specialty distribution and international expansion. Wall Street analysts maintain a constructive view, issuing "Buy" or "Overweight" ratings and expressing confidence in the company's strategic repositioning and consistent free cash flow generation.

**3. The Truth About Cardinal Health Inc.: Quiet Stock, Loud Moves â€“ Are You Sleeping On This Play?**
- Source: AD HOC NEWS | 20251231T181342 | Somewhat-Bullish | Relevance: 62%
- Cardinal Health Inc. recently showed significant market activity, prompting a closer look at whether this healthcare stock is a valuable investment or just a quiet performer. The article explores Cardinal Health's role in the healthcare supply chain, its recent financial performance, and its position against competitors like McKesson and AmerisourceBergen. It aims to help investors decide if this "quiet operator" is a "cop" for long-term, defensive portfolios or a "drop" for those seeking short-term gains.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $65.7B |
| Beta | 0.63 |
| 52W Range | $227.95 - $377.54 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.4 |
| Current P/E | 19.3 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.8% to 0.3% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.7pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 43. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.31% (CS: 42) | Neutral |
| RSI_14 | 42.7 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.973x | Below |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $338.87
- **Stop Loss:** $327.89 (3.2% risk)
- **Target:** $349.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 131
- **Position Value:** $44,391.97
- **Portfolio %:** 44.39%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*